Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir)
Brand Names: Vosevi
Methodology & AI Transparency ⓘ
Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor category, Vosevi provides branded delivery of active pharmaceutical ingredient Sofosbuvir, Velpatasvir, and Voxilaprevir (registered by Gilead Sciences, Inc.; NDC 61958-2401).
- 2 Real-world patient consensus: Registered under RxNorm RXN-B619582401 and SPL 2026-07-01, pairing Vosevi packaging with active ingredient Sofosbuvir, Velpatasvir, and Voxilaprevir.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $640.00 cash mean against $1696.00 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir)): nausea (9.4%), headache (8.6%), dizziness (6.9%).
Ask our AI Specialists anything about Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir)
Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor category, Vosevi provides branded delivery of active pharmaceutical ingredient Sofosbuvir, Velpatasvir, and Voxilaprevir (registered by Gilead Sciences, Inc.; NDC 61958-2401). Characterized by 400 mg/1 / 100 mg/1 Tablet, Film Coated; 400 mg under 2026-07-01 SPL documentation, Vosevi targets FDA-labeled hepatitis c virus nucleotide analog ns5b polymerase inhibitor clinical management protocols.
Through its Sofosbuvir, Velpatasvir, and Voxilaprevir active moiety, Vosevi exerts hepatitis c virus nucleotide analog ns5b polymerase inhibitor activity with class-characteristic hepatorenal disposition. Registered under NDC 61958-2401 (registered by Gilead Sciences, Inc.; effective 2026-07-01), the 400 mg/1 / 100 mg/1 Tablet, Film Coated; 400 mg presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (RXN-B619582401) and CMS NADAC ($278.3091/unit) ledgers.
Systemic exposure to Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) reflects Estimated 73%–85% oral systemic absorption for Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) absorption kinetics and phase i/ii hepatic conjugation of vosevi (sofosbuvir, velpatasvir, and voxilaprevir) coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 9–22 hours terminal plasma half-life for Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) half-life window (peak plasma concentration (tmax) reached 1–2 hours post-dose for vosevi (sofosbuvir, velpatasvir, and voxilaprevir) response profile).
Dosing protocols (400 mg/1 / 100 mg/1 Tablet, Film Coated or 400 mg or 100 mg/1 Tablet) balance efficacy (74.00% patient satisfaction across 16 logs) against nausea (9.4% of reports), headache (8.6% of reports), dizziness (6.9% of reports), with strict avoidance in severe drug-induced hypersensitivity to sofosbuvir, velpatasvir, and voxilaprevir or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-07-01 for vosevi (sofosbuvir, velpatasvir, and voxilaprevir).
Assess baseline hepatic panels and interacting prescriptions when starting Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) (hepatitis c virus nucleotide analog ns5b polymerase inhibitor).
Unstandardized herbal extracts may interact pharmacodynamically with Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Sofosbuvir, Velpatasvir, and Voxilaprevir or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-07-01 for Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir)
Logged Side-Effect Incidence (16 Reports)
Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir))
Human clinical trial evidence for Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $278.3091/unit (~$8349.27/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) RxNorm Concept ID | RXN-B619582401 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $278.3091 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Patient Community, Cohort Filters & Dosage Logs
Deterministic Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) reference combining NIH RxNorm (RXN-B619582401), Medicaid NADAC ($278.3091/unit), and anonymous cohort outcomes (74% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) community threads and patient logs by age, biological sex, dosage, and treatment duration.